Response of 1,5‐anhydroglucitol level to intensive glucose‐ and blood‐pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial

Response of 1,5‐anhydroglucitol level to intensive glucose‐ and blood‐pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial

<p><strong>Aims</strong></p> <p>To evaluate 1,5‐anhydroglucitol (1,5‐AG) according to clinical outcomes and assess the effects of glucose‐ and blood pressure‐lowering interventions on change in 1,5‐AG levels in people with type 2 diabetes.</p> <p><strong...

Полное описание

Библиографические подробности
Главные авторы:	Selvin, E, Wang, D, McEvoy, JW, Juraschek, SP, Lazo, M, Hamet, P, Cooper, ME, Marre, M, Williams, B, Harrap, S, Chalmers, J, Woodward, M
Формат:	Journal article
Язык:	English
Опубликовано:	Wiley 2019

Схожие документы

Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial
по: Rahman, F, и др.
Опубликовано: (2019)

Genome-wide association study of 1,5-anhydroglucitol identifies novel genetic loci linked to glucose metabolism
по: Man Li, и др.
Опубликовано: (2017-06-01)

Data for serum 1,5 anhydroglucitol concentration in different populations
по: Marciane Welter, и др.
Опубликовано: (2018-10-01)

The clinical potential of 1,5-anhydroglucitol as biomarker in diabetes mellitus
по: Haiying Xu, и др.
Опубликовано: (2024-10-01)

The Use of 1.5-Anhydroglucitol for Monitoring Glycemic Control in Islet Transplant Recipients
по: Eduardo Moraes Leao Peixoto, и др.
Опубликовано: (2014-10-01)

The use of 1,5 anhydroglucitol level as a clinical test to differentiate subtypes of diabetes
по: Owen, K, и др.
Опубликовано: (2009)

Intensive glucose lowering and the risk of vascular events and premature death in patients with decreased kidney function: the ADVANCE trial
по: Ohkuma, T, и др.
Опубликовано: (2019)

Pemeriksaan 1,5-Anhydroglucitol, Suatu Hal Baru dalam Pemeriksaan Prediabetes
по: Reza Febryan
Опубликовано: (2024-03-01)

Value of serum 1,5-anhydroglucitol measurements in childhood obesity in the continuum of diabetes
по: Ha Yeong Yoo, и др.
Опубликовано: (2015-12-01)

The progress of clinical research on the detection of 1,5-anhydroglucitol in diabetes and its complications
по: Huijuan Xu, и др.
Опубликовано: (2024-05-01)

Side-effects and tolerability of combination blood pressure lowering according to blood pressure levels – an analysis of the PROGRESS and ADVANCE trials
по: Atkins, A, и др.
Опубликовано: (2017)

Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes.
по: Pal, A, и др.
Опубликовано: (2010)

History of lower-limb complications and risk of cancer death in people with type 2 diabetes
по: Kamel Mohammedi, и др.
Опубликовано: (2021-01-01)

Prognostic Value of Serum 1,5-anhydroglucitol Levels in Patients with Acute Myocardial Infarction
по: Yijia Wang, и др.
Опубликовано: (2022-12-01)

Relationship of glycemic control markers - 1,5 anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance
по: Thyparambil Aravindakshan Pramodkumar, и др.
Опубликовано: (2016-01-01)

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
по: Zoungas, S, и др.
Опубликовано: (2009)

1,5-anhydroglucitol in diabetes: its role in diagnostics, screening, glycemic status assessment, and the prediction of complications
по: V. V. Klimontov, и др.
Опубликовано: (2020-08-01)

Alternative biomarkers for assessing glycemic control in diabetes: fructosamine, glycated albumin, and 1,5-anhydroglucitol
по: Ji-Eun Lee
Опубликовано: (2015-06-01)

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
по: Patel, A, и др.
Опубликовано: (2008)

Lowering blood pressure reduces renal events in type 2 diabetes.
по: de Galan, B, и др.
Опубликовано: (2009)

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.
по: Perkovic, V, и др.
Опубликовано: (2013)

1,5-anhydroglucitol is a good predictor for the treatment effect of the Sodium-Glucose cotransporter 2 inhibitor in Japanese patients with type 2 diabetes mellitus
по: Masahiro Usui, и др.
Опубликовано: (2020-09-01)

Use of the waist‐to‐height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE‐ON study
по: Rådholm, K, и др.
Опубликовано: (2018)

Effect of 1,5-anhydroglucitol levels on culprit plaque rupture in diabetic patients with acute coronary syndrome
по: Gong Su, и др.
Опубликовано: (2020-05-01)

Estimating individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes
по: Woodward, M, и др.
Опубликовано: (2016)

Serum levels of 1,5-anhydroglucitol and 1,5-anhydrofructose-derived advanced glycation end products in patients undergoing hemodialysis
по: Kenji Tanaka, и др.
Опубликовано: (2021-08-01)

Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study
по: Mohammedi, K, и др.
Опубликовано: (2016)

Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes
по: Mohammedi, K, и др.
Опубликовано: (2017)

Saliva 1,5-anhydroglucitol is associated with early-phase insulin secretion in Chinese patients with type 2 diabetes
по: Jian Zhou, и др.
Опубликовано: (2021-03-01)

1,5-Anhydroglucitol as a Useful Marker for Assessing Short-Term Glycemic Excursions in Type 1 Diabetes
по: Hannah Seok, и др.
Опубликовано: (2015-04-01)

Evaluation of 1,5-Anhydroglucitol as a Biomarker for Type 2 Diabetes Mellitus in Patients without Overt Nephropathy
по: Luiza Cristina Gobor, и др.
Опубликовано: (2021-10-01)

Detection of 1,5-anhydroglucitol as a Biomarker for Diabetes Using an Organic Field-Effect Transistor-Based Biosensor
по: Hiroyuki Furusawa, и др.
Опубликовано: (2018-08-01)

Human and mouse non‐targeted metabolomics identify 1,5‐anhydroglucitol as SGLT2‐dependent glycemic marker
по: Ben A. Kappel, и др.
Опубликовано: (2021-06-01)

Association between 1,5-Anhydroglucitol and Acute C Peptide Response to Arginine among Patients with Type 2 Diabetes
по: Yun Shen, и др.
Опубликовано: (2020-01-01)

Nonlinear association of 1,5-anhydroglucitol with the prevalence and severity of coronary artery disease in chinese patients undergoing coronary angiography
по: Ruiyue Yang, и др.
Опубликовано: (2022-09-01)

Evaluation of serum 1,5-anhydroglucitol levels as hyperglycemic indicator in patients with newly diagnosed type 2 diabetes mellitus
по: Ashok Vanagamudi, и др.
Опубликовано: (2022-01-01)

Absence of peripheral pulses and risk of major vascular outcomes in patients with type 2 diabetes
по: Mohammedi, K, и др.
Опубликовано: (2016)

The relationship between serum 1,5-anhydroglucitol and adverse outcomes in acute coronary syndrome with and without chronic kidney disease patients
по: Yijia Wang, и др.
Опубликовано: (2024-07-01)

1,5-Anhydroglucitol promotes pre-B acute lymphocytic leukemia progression by driving glycolysis and reactive oxygen species formation
по: Huasu Zhu, и др.
Опубликовано: (2023-02-01)

The impact of level of education on vascular events and mortality in patients with type 2 Diabetes mellitus: results from the ADVANCE study
по: Blomster, J, и др.
Опубликовано: (2017)